Chronic inflammation promotes epithelial-mesenchymal transition-mediated malignant phenotypes and lung injury in experimentally-induced pancreatitis.
Azoxymethane
Cerulein
Chronic pancreatitis
Eosinophils
IL-15
Malignancy
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Aug 2021
01 Aug 2021
Historique:
received:
21
03
2021
revised:
12
05
2021
accepted:
21
05
2021
pubmed:
29
5
2021
medline:
29
6
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
Patients with chronic pancreatitis have an increased risk of pancreatic malignancy, but the mechanisms underlying this relationship are poorly understood. We developed a mouse model of chronic pancreatitis by treatment with a combination of cerulein and azoxymethane. In our model, we show that cerulein and azoxymethane treated mice develop pathological malignant phenotype and associated lung inflammation. We observed chronic pancreatitis-associated induction of proinflammatory cytokines such as interleukin-6, interleukin-15, and granulocyte-macrophage colony-stimulating factor, along with accumulation of macrophages and eosinophilic inflammation. We also observed eosinophils degranulation, pancreatic stellate cell activation-mediated epithelial-to-mesenchymal transition-associated proteins that display a pancreatic malignant phenotype including acinar-to-ductal metaplasia and acinar cell atrophy. We observed highly induced interleukin-15 that has been earlier reported to have a protective role against fibrosis and malignancy; therefore, further evaluated its role in our mouse model of chronic pancreatitis. We observed that introduction of recombinant interleukin-15 has indeed improve chronic pancreatitis-associated epithelial-to-mesenchymal transition-mediated development of a malignant phenotype in the mouse model of chronic pancreatitis. In conclusion, we present evidence that rIL-15 overexpression improves eosinophilic inflammation-induced epithelial-to-mesenchymal transition-mediated progression of pancreatic remodeling associated malignant phenotype and acute lung injury by inducing NKT cells and IFN-γ mediated innate immunity in experimental pancreatitis.
Identifiants
pubmed: 34048812
pii: S0024-3205(21)00626-3
doi: 10.1016/j.lfs.2021.119640
pmc: PMC8245354
mid: NIHMS1709858
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119640Subventions
Organisme : NIAID NIH HHS
ID : R01 AI080581
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Endocr Metab Immune Disord Drug Targets. 2020;20(8):1182-1210
pubmed: 32324526
World J Gastroenterol. 2017 Nov 7;23(41):7440-7449
pubmed: 29151698
Am J Physiol Gastrointest Liver Physiol. 2018 Feb 1;314(2):G211-G222
pubmed: 28935682
Turk J Gastroenterol. 2013;24(6):502-7
pubmed: 24623289
J Allergy Clin Immunol. 2018 Mar;141(3):906-917.e6
pubmed: 28606589
Genes Dev. 2006 Nov 15;20(22):3130-46
pubmed: 17114584
World J Gastroenterol. 2019 Jul 21;25(27):3503-3526
pubmed: 31367153
Genes Dev. 2003 Dec 15;17(24):3112-26
pubmed: 14681207
Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S40-3
pubmed: 19896097
Int Rev Cell Mol Biol. 2015;314:1-41
pubmed: 25619714
Dig Dis Sci. 2017 Dec;62(12):3287-3297
pubmed: 29086330
Cold Spring Harb Symp Quant Biol. 2005;70:65-72
pubmed: 16869739
J Immunol. 2011 Dec 15;187(12):6335-45
pubmed: 22084435
Am J Pathol. 1993 Jan;142(1):11-6
pubmed: 8424449
Digestion. 1995;56(3):246-52
pubmed: 7544747
Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6
pubmed: 19501586
Int J Oncol. 2016 Feb;48(2):783-92
pubmed: 26647741
Gastroenterology. 2013 Jun;144(6):1220-9
pubmed: 23622131
Cell Commun Signal. 2020 Jun 17;18(1):95
pubmed: 32552827
Endocr Metab Immune Disord Drug Targets. 2021;21(2):203-214
pubmed: 32416712
Adv Cancer Res. 2008;101:277-348
pubmed: 19055947
Immunology. 2021 Jun;163(2):220-235
pubmed: 33512727
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G265-G276
pubmed: 31760766
Mod Pathol. 2019 Jun;32(6):799-806
pubmed: 30643167
Acta Pharmacol Sin. 2007 Sep;28(9):1450-9
pubmed: 17723178
Oncogene. 2017 Jul 27;36(30):4336-4348
pubmed: 28368414
Am J Gastroenterol. 2011 Dec;106(12):2192-9
pubmed: 21946280
Curr Opin Crit Care. 2002 Apr;8(2):158-63
pubmed: 12386518
Nat Rev Gastroenterol Hepatol. 2017 May;14(5):296-304
pubmed: 28270694
Front Immunol. 2020 Jan 17;10:3013
pubmed: 32010130
Am J Respir Cell Mol Biol. 2019 Jul;61(1):97-109
pubmed: 30702923
Eur Surg Res. 2010;44(3-4):159-69
pubmed: 20332642
CA Cancer J Clin. 2003 Jul-Aug;53(4):245-55
pubmed: 12924777
Clin Transl Immunology. 2020 Aug 15;9(8):e1165
pubmed: 32821382
Cytokine Growth Factor Rev. 2019 Jun;47:83-98
pubmed: 31126874
Cancer Cell. 2003 Dec;4(6):437-50
pubmed: 14706336
J Immunol. 2001 Nov 15;167(10):5948-54
pubmed: 11698473
Crit Care Med. 2016 Aug;44(8):e664-77
pubmed: 26963319
Am J Physiol Gastrointest Liver Physiol. 2018 Dec 1;315(6):G954-G965
pubmed: 30212254